Details of the Drug

General Information of Drug (ID: DM98IXF)

Drug Name
Triamcinolone
Synonyms
Adcortyl; Aristocort; Celeste; Cinolone; Delphicort; Fluoxiprednisolone; Fluoxyprednisolone; Fougera; Ione; Kenacort; Ledercort; Mycolog; Omcilon; Omicilon; Orion; Rodinolone; Tiamcinolonum; Triamcet; Triamcinalone; Triamcinlon; Triamcinolon; Triamcinolona; Triamcinolonum; Tricortale; Trilone; Tristoject; Volon; Aristocort Tablets; Triamcinolonum [INN]; CL 19823; Aristocort (TN); Azmacort (TN); Cinolone-T; Fougera (TN); Kenacort (TN); Kenacort-AG; Kenalog (TN); Nasacort (TN); SK-Triamcinolone; Tiamcinolonum [INN-Latin]; Triam-Tablinen; Triamcinolona [INN-Spanish]; Tricortone (TN); Triderm (TN); Triesence (TN); Trilone (TN); Tristoject (TN); Volon A (TN); Tri-Nasal (TN); Triamcinolone (JP15/USP/INN); Triamcinolone [USAN:INN:BAN:JAN]; Droxypregna-1,4-diene-3,20-dione; Pregna-1,4-diene-3,20-dio; TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7)); Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy-(8CI); Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha); (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; 11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione; 11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione; 9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-hydroxyprednisolone; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d; 9.Alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione; 9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione; 9alpha-Fluoro-16alpha-hydroxyprednisolone
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 394.4
Topological Polar Surface Area (xlogp) 1.2
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 36.0 +/- 6.2 mcgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 5.23 +/- 0.84 mcg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2.24 +/- 0.78 h [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The total body clearance of drug is 0.57 L/h [2]
Elimination
Approximately 20% of a dose of triamcinolone is recovered in the urine as the unchanged drug, 25% is recovered as 6-beta-hydroxy-triamcinolone, and 5% is recovered as unidentified metabolites [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.7 hours [2]
Vd
The volume of distribution (Vd) of drug is 115.2 +/- 10 L [2]
Water Solubility
The ability of drug to dissolve in water is measured as 0.08 mg/mL [3]
Chemical Identifiers
Formula
C21H27FO6
IUPAC Name
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES
C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O
InChI
InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
InChIKey
GFNANZIMVAIWHM-OBYCQNJPSA-N
Cross-matching ID
PubChem CID
31307
ChEBI ID
CHEBI:9667
CAS Number
124-94-7
DrugBank ID
DB00620
TTD ID
D03BLF
ACDINA ID
D01501

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Triamcinolone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Triamcinolone due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [12]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Triamcinolone caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [13]
Posaconazole DMUL5EW Major Decreased metabolism of Triamcinolone caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [14]
Levalbuterol DM5YBO1 Minor Increased risk of hypokalemia by the combination of Triamcinolone and Levalbuterol. Asthma [CA23] [15]
Terbutaline DMD4381 Minor Increased risk of hypokalemia by the combination of Triamcinolone and Terbutaline. Asthma [CA23] [14]
Pirbuterol DMI5678 Minor Increased risk of hypokalemia by the combination of Triamcinolone and Pirbuterol. Asthma [CA23] [14]
Salbutamol DMN9CWF Minor Increased risk of hypokalemia by the combination of Triamcinolone and Salbutamol. Asthma [CA23] [15]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Roflumilast. Asthma [CA23] [16]
Formoterol DMSOURV Minor Increased risk of hypokalemia by the combination of Triamcinolone and Formoterol. Asthma [CA23] [14]
Ofloxacin DM0VQN3 Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Ofloxacin. Bacterial infection [1A00-1C4Z] [17]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Triamcinolone caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [18]
Clarithromycin DM4M1SG Major Decreased metabolism of Triamcinolone caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Trovafloxacin DM6AN32 Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Trovafloxacin. Bacterial infection [1A00-1C4Z] [17]
Sparfloxacin DMB4HCT Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Sparfloxacin. Bacterial infection [1A00-1C4Z] [17]
Gemifloxacin DMHT34O Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Gemifloxacin. Bacterial infection [1A00-1C4Z] [17]
Norfloxacin DMIZ6W2 Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Norfloxacin. Bacterial infection [1A00-1C4Z] [17]
ABT-492 DMJFD2I Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and ABT-492. Bacterial infection [1A00-1C4Z] [17]
Levofloxacin DMS60RB Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Levofloxacin. Bacterial infection [1A00-1C4Z] [17]
Troleandomycin DMUZNIG Major Decreased metabolism of Triamcinolone caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Lomefloxacin DMVRH9C Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Lomefloxacin. Bacterial infection [1A00-1C4Z] [17]
Telithromycin DMZ4P3A Major Decreased metabolism of Triamcinolone caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Triamcinolone caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [19]
Tucatinib DMBESUA Major Decreased metabolism of Triamcinolone caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [14]
Vilanterol DMF5EK1 Minor Increased risk of hypokalemia by the combination of Triamcinolone and Vilanterol. Chronic obstructive pulmonary disease [CA22] [15]
Salmeterol DMIEU69 Minor Increased risk of hypokalemia by the combination of Triamcinolone and Salmeterol. Chronic obstructive pulmonary disease [CA22] [14]
Indacaterol DMQJHR7 Minor Increased risk of hypokalemia by the combination of Triamcinolone and Indacaterol. Chronic obstructive pulmonary disease [CA22] [14]
Arformoterol DMYM974 Minor Increased risk of hypokalemia by the combination of Triamcinolone and Arformoterol. Chronic obstructive pulmonary disease [CA22] [14]
Phenylbutazone DMAYL0T Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Phenylbutazone. Chronic pain [MG30] [20]
Ketoprofen DMRKXPT Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Ketoprofen. Chronic pain [MG30] [20]
Isoproterenol DMK7MEY Minor Increased risk of hypokalemia by the combination of Triamcinolone and Isoproterenol. Conduction disorder [BC63] [15]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Triamcinolone and Mivacurium. Corneal disease [9A76-9A78] [14]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Triamcinolone and Pancuronium. Corneal disease [9A76-9A78] [14]
Tubocurarine DMBZIVP Moderate Additive neuromuscular blocking effects by the combination of Triamcinolone and Tubocurarine. Corneal disease [9A76-9A78] [14]
Mifepristone DMGZQEF Major Decreased metabolism of Triamcinolone caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [21]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Triamcinolone caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [22]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Triamcinolone caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [23]
MK-8228 DMOB58Q Moderate Decreased metabolism of Triamcinolone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [24]
Nefazodone DM4ZS8M Major Decreased metabolism of Triamcinolone caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [14]
Primidone DM0WX6I Moderate Increased metabolism of Triamcinolone caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Triamcinolone caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Cenobamate DMGOVHA Moderate Increased metabolism of Triamcinolone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [27]
Stiripentol DMMSDOY Moderate Decreased metabolism of Triamcinolone caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Triamcinolone caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Rufinamide DMWE60C Moderate Increased metabolism of Triamcinolone caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Ethotoin DMXWOCP Moderate Increased metabolism of Triamcinolone caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Phenobarbital DMXZOCG Moderate Increased metabolism of Triamcinolone caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Mefenamic acid DMK7HFI Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Mefenamic acid. Female pelvic pain [GA34] [20]
Tazemetostat DMWP1BH Moderate Increased metabolism of Triamcinolone caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [30]
Itraconazole DMCR1MV Major Decreased metabolism of Triamcinolone caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [14]
Miconazole DMPMYE8 Moderate Decreased metabolism of Triamcinolone caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [31]
Ketoconazole DMPZI3Q Major Decreased metabolism of Triamcinolone caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [14]
Bumetanide DMRV7H0 Moderate Increased risk of hypokalemia by the combination of Triamcinolone and Bumetanide. Heart failure [BD10-BD1Z] [32]
Boceprevir DMBSHMF Major Decreased metabolism of Triamcinolone caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [14]
Telaprevir DMMRV29 Major Decreased metabolism of Triamcinolone caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [14]
Rifampin DMA8J1G Moderate Increased metabolism of Triamcinolone caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [33]
Rifapentine DMCHV4I Moderate Increased metabolism of Triamcinolone caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [34]
Delavirdine DM3NF5G Major Decreased metabolism of Triamcinolone caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Triamcinolone caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Cobicistat DM6L4H2 Major Decreased metabolism of Triamcinolone caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Efavirenz DMC0GSJ Moderate Increased metabolism of Triamcinolone caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Saquinavir DMG814N Major Decreased metabolism of Triamcinolone caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Etravirine DMGV8QU Moderate Increased metabolism of Triamcinolone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Amprenavir DMLMXE0 Major Decreased metabolism of Triamcinolone caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Darunavir DMN3GCH Moderate Decreased metabolism of Triamcinolone caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Atazanavir DMSYRBX Major Decreased metabolism of Triamcinolone caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [37]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Triamcinolone and Teriflunomide. Hyper-lipoproteinaemia [5C80] [38]
Conivaptan DM1V329 Major Decreased metabolism of Triamcinolone caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [14]
Meclofenamic acid DM05FXR Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [39]
Amobarbital DM0GQ8N Moderate Increased metabolism of Triamcinolone caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [25]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Denosumab. Low bone mass disorder [FB83] [40]
Ceritinib DMB920Z Major Decreased metabolism of Triamcinolone caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [14]
PF-06463922 DMKM7EW Moderate Increased metabolism of Triamcinolone caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [41]
Idelalisib DM602WT Major Decreased metabolism of Triamcinolone caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [14]
IPI-145 DMWA24P Moderate Decreased metabolism of Triamcinolone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [42]
Nivolumab DMAB9QE Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Nivolumab. Melanoma [2C30] [14]
Pembrolizumab DMFQEA6 Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Pembrolizumab. Melanoma [2C30] [14]
Ipilimumab DMJTIYK Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Ipilimumab. Melanoma [2C30] [14]
Cemiplimab DMKMJHE Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Cemiplimab. Melanoma [2C30] [14]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Triamcinolone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [16]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Triamcinolone and Thalidomide. Multiple myeloma [2A83] [43]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Tecfidera. Multiple sclerosis [8A40] [44]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Triamcinolone and Siponimod. Multiple sclerosis [8A40] [15]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Triamcinolone and Fingolimod. Multiple sclerosis [8A40] [45]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Ocrelizumab. Multiple sclerosis [8A40] [46]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Triamcinolone and Ozanimod. Multiple sclerosis [8A40] [16]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Triamcinolone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [14]
Nilotinib DM7HXWT Moderate Decreased metabolism of Triamcinolone caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [47]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [48]
Modafinil DMYILBE Minor Increased metabolism of Triamcinolone caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [49]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Triamcinolone and Bupropion. Nicotine use disorder [6C4A] [50]
Atezolizumab DMMF8U0 Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Atezolizumab. Non-small cell lung cancer [2C25] [14]
Naproxen DMZ5RGV Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Naproxen. Osteoarthritis [FA00-FA05] [20]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Triamcinolone caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [51]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Aspirin. Pain [MG30-MG3Z] [52]
Etodolac DM6WJO9 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Etodolac. Pain [MG30-MG3Z] [20]
Diflunisal DM7EN8I Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Diflunisal. Pain [MG30-MG3Z] [20]
Ibuprofen DM8VCBE Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Ibuprofen. Pain [MG30-MG3Z] [20]
Abametapir DM2RX0I Moderate Decreased metabolism of Triamcinolone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [53]
Choline salicylate DM8P137 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Choline salicylate. Postoperative inflammation [1A00-CA43] [54]
Bromfenac DMKB79O Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Bromfenac. Postoperative inflammation [1A00-CA43] [20]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Triamcinolone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [14]
Ritodrine DM4V6RL Minor Increased risk of hypokalemia by the combination of Triamcinolone and Ritodrine. Preterm labour/delivery [JB00] [14]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Triamcinolone and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [55]
Gatifloxacin DMSL679 Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Gatifloxacin. Respiratory infection [CA07-CA4Z] [17]
Salsalate DM13P4C Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Salsalate. Rheumatoid arthritis [FA20] [54]
Meloxicam DM2AR7L Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Meloxicam. Rheumatoid arthritis [FA20] [20]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Canakinumab. Rheumatoid arthritis [FA20] [56]
Oxaprozin DM9UB0P Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Oxaprozin. Rheumatoid arthritis [FA20] [20]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Rilonacept. Rheumatoid arthritis [FA20] [56]
Flurbiprofen DMGN4BY Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Flurbiprofen. Rheumatoid arthritis [FA20] [20]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Triamcinolone and Golimumab. Rheumatoid arthritis [FA20] [57]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Triamcinolone and Leflunomide. Rheumatoid arthritis [FA20] [38]
Salicyclic acid DM2F8XZ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Salicyclic acid. Seborrhoeic dermatitis [EA81] [52]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Triamcinolone when combined with Anthrax vaccine. Sepsis [1G40-1G41] [58]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Triamcinolone caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [14]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Triamcinolone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [16]
Larotrectinib DM26CQR Moderate Decreased metabolism of Triamcinolone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [15]
Armodafinil DMGB035 Minor Increased metabolism of Triamcinolone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [49]
LEE011 DMMX75K Moderate Decreased metabolism of Triamcinolone caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [59]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Triamcinolone and Pitolisant. Somnolence [MG42] [16]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Triamcinolone caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [60]
Pipecuronium DM5F84A Moderate Additive neuromuscular blocking effects by the combination of Triamcinolone and Pipecuronium. Tonus and reflex abnormality [MB47] [14]
Doxacurium DMKE7L9 Moderate Additive neuromuscular blocking effects by the combination of Triamcinolone and Doxacurium. Tonus and reflex abnormality [MB47] [14]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Triamcinolone and Vecuronium. Tonus and reflex abnormality [MB47] [14]
Rocuronium DMY9BMK Moderate Additive neuromuscular blocking effects by the combination of Triamcinolone and Rocuronium. Tonus and reflex abnormality [MB47] [14]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Triamcinolone and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [55]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Triamcinolone and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [55]
Durvalumab DM4PVDY Moderate Additive immunosuppressive effects by the combination of Triamcinolone and Durvalumab. Ureteral cancer [2C92] [14]
Cinoxacin DM4EWNS Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Cinoxacin. Urinary tract infection [GC08] [17]
Nalidixic acid DMRM0JV Major Increased risk of tendinitis/tendon rupture by the combination of Triamcinolone and Nalidixic acid. Urinary tract infection [GC08] [17]
⏷ Show the Full List of 131 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Hydrochloric acid E00015 313 Acidulant
Benzalkonium chloride E00536 21988052 Antimicrobial preservative; Penetration agent; Solubilizing agent; Surfactant
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Dextrose anhydrous E00394 107526 Binding agent; Diluent; Flavoring agent; Tonicity agent
Edetate disodium E00186 8759 Complexing agent
Nitrogen E00033 947 Aerosol propellant; Sparging agent
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Water E00035 962 Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Triamcinolone 55ug spray 55ug Spray Nasal
Triamcinolone 40mg/ml suspension 40mg/ml Suspension Intramuscular; Intraarticular
Triamcinolone 0.05% ointment 0.05% Ointment Topical
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Oral bioavailability of triamcinolone tablets and a triamcinolone diacetate suspension. Pharm Res. 1990 May;7(5):558-60. doi: 10.1023/a:1015889305157.
3 BDDCS applied to over 900 drugs
4 FLORINI JR, SMITH LL, BUYSKE DA: Metabolic fate of a synthetic corticosteroid (triamcinolone) in the dog. J Biol Chem. 1961 Apr;236:1038-42.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
7 Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
8 Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
9 Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
10 PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
11 The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
12 Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
13 Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8. [PMID: 4553339]
14 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
15 Cerner Multum, Inc. "Australian Product Information.".
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
18 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
19 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
20 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
21 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
22 Cerner Multum, Inc. "Canadian Product Information.".
23 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
24 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
25 Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
26 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
27 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
28 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
29 Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
30 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
31 Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
32 Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2. [PMID: 8468765]
33 Kyriazopoulou V, Parparousi O, Vagenakis AG "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab 59 (1984): 1204-6. [PMID: 6490796]
34 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
35 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
36 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
37 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
38 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
39 Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4. [PMID: 6343871]
40 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
41 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
43 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
44 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
45 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
46 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
47 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
48 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
49 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
50 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
51 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
52 Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
53 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
54 Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
55 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
56 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
57 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
58 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
59 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
60 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.